The earnings surpassed analyst expectations with an adjusted earnings per share (EPS) of $1.19, beating estimates of $0.91 by ...

Leerink Partnrs upgraded shares of CVS Health (NYSE:CVS – Free Report) from a hold rating to a strong-buy rating in a ...

CVS Health posted Q4 sales of $97.71B, with a 23.3% rise in Health Care Benefits revenue. Fiscal 2025 adjusted EPS guidance ...

CEO David Joyner highlighted the company's Q4 adjusted EPS of $1.19 and adjusted operating income of $2.7 billion. He introduced 2025 adjusted EPS guidance of $5.75 to $6.00, emphasizing recovery in ...

Sees FY25 free cash flow $6.5B. The company said, “The Company issued its full-year 2025 GAAP diluted EPS guidance range of $4.58 to $4.83 and ...

Full Year 2024 Results Key Financial Results Revenue: US$372.8b (up 4.5% from FY 2023).

Adjusted EPS of $1.19 decreased from $2.12 in the prior year, beating the consensus of $0.93, primarily due to a decline in ...

Troubled drugstore chain CVS Health (CVS) reported Fiscal fourth-quarter results that beat on the top and bottom lines, ...

Pharmacy retailer CVS Health Inc. (NYSE:CVS) is scheduled to report its fourth quarter 2024 earnings on Wednesday,2. Wall ...

Shares of CVS Health Corporation (NYSE: CVS) experienced a jolt, rising over 15% on February 12, 2025, as the market responded to the release of its fourth-quarter 2024 earnings report. CVS Health's ...

Guidance: CVS Health forecasts fiscal year 2025 adjusted EPS of $5.75-$6.00 versus consensus of $5.96. The company expects GAAP EPS of $4.58 to $4.83, with cash flow from operations guidance of ...

CVS provided initial 2025 adjusted EPS guidance in the range of $5.75 to $6.00. This reflects expected improvements in Aetna's Medicare Advantage margins and a multi-year $2 billion cost ...